JOHNSON & JOHNSON is 406.7x more valuable than ArriVent BioPharma, Inc. by market capitalization ($573.98 B vs $1.41 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AVBP | JNJ |
|---|---|---|
| Market cap | $1.41 B | $573.98 B |
| US-listed rank | #2376 | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | -$166.31M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 144 | 984 |
JOHNSON & JOHNSON is 406.7x more valuable than ArriVent BioPharma, Inc. by market capitalization ($573.98 B vs $1.41 B).
Full pages: ArriVent BioPharma, Inc. and JOHNSON & JOHNSON, or browse the full rankings.